These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 30028180)
21. Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of Medaer E; Verslype C; Van Cutsem E; Dekervel J; Clement PM; Nackaerts K; Laenen A; Gheysens O; Goffin K; Jentjens S; Van Laere K; Deroose CM Acta Oncol; 2020 Jun; 59(6):644-651. PubMed ID: 32036716 [No Abstract] [Full Text] [Related]
22. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205 [TBL] [Abstract][Full Text] [Related]
23. 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors. Jahn U; Ilan E; Sandström M; Garske-Román U; Lubberink M; Sundin A Neuroendocrinology; 2020; 110(7-8):662-670. PubMed ID: 31597134 [TBL] [Abstract][Full Text] [Related]
24. Super-selective hepatic arterial infusions as established technique ('ARETAIEION' Protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors. Limouris GS; Karfis I; Chatzioannou A; Paphiti MI; Lyra M; Gennatas K; Nikou G; Voros D; Pragulidis GP; Polydorou AA; Gouliamos A Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):551-8. PubMed ID: 23358409 [TBL] [Abstract][Full Text] [Related]
25. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115 [TBL] [Abstract][Full Text] [Related]
26. Prediction of Mileva M; Marin G; Levillain H; Artigas C; Van Bogaert C; Marin C; Danieli R; Deleporte A; Picchia S; Stathopoulos K; Jungels C; Vanderlinden B; Paesmans M; Ameye L; Critchi G; Taraji-Schiltz L; Velghe C; Wimana Z; Bali M; Hendlisz A; Flamen P; Karfis I J Nucl Med; 2024 Feb; 65(2):236-244. PubMed ID: 38164576 [TBL] [Abstract][Full Text] [Related]
27. Biodistribution, Pharmacokinetics, and Dosimetry of Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554 [TBL] [Abstract][Full Text] [Related]
28. Gastroenteropancreatic Neuroendocrine Tumors. Cives M; Strosberg JR CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930 [TBL] [Abstract][Full Text] [Related]
29. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222 [TBL] [Abstract][Full Text] [Related]
30. Twins in spirit part IV - [ Brogsitter C; Hartmann H; Wunderlich G; Schottelius M; Wester HJ; Kotzerke J Nuklearmedizin; 2017 Feb; 56(1):1-8. PubMed ID: 28138688 [TBL] [Abstract][Full Text] [Related]
31. Patient external dose rate after Zhang-Yin J; Guilabert N; Kiffel T; Montravers F; Calais P; Lumbroso J; Talbot JN Int J Med Sci; 2021; 18(12):2725-2735. PubMed ID: 34104105 [No Abstract] [Full Text] [Related]
32. A dosimetry procedure for organs-at-risk in Marin G; Vanderlinden B; Karfis I; Guiot T; Wimana Z; Reynaert N; Vandenberghe S; Flamen P Phys Med; 2018 Dec; 56():41-49. PubMed ID: 30527088 [TBL] [Abstract][Full Text] [Related]
33. Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy. Kletting P; Kull T; Maaß C; Malik N; Luster M; Beer AJ; Glatting G J Nucl Med; 2016 Apr; 57(4):503-8. PubMed ID: 26678617 [TBL] [Abstract][Full Text] [Related]
34. Long-Term Efficacy, Survival, and Safety of [ Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192 [No Abstract] [Full Text] [Related]
35. Dosimetry of Xu L; Meng Q; Yao X; Yang R; Zhang P; Li R; Wang F Appl Radiat Isot; 2022 Jan; 179():109975. PubMed ID: 34741954 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of the Interaction of Amino Acid Infusion on Puszkiel A; Bauriaud-Mallet M; Bourgeois R; Dierickx L; Courbon F; Chatelut E Clin Pharmacokinet; 2019 Feb; 58(2):213-222. PubMed ID: 29736841 [TBL] [Abstract][Full Text] [Related]
37. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388 [TBL] [Abstract][Full Text] [Related]
38. Additional hepatic Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988 [TBL] [Abstract][Full Text] [Related]